NFKB1 and diffuse large B-cell lymphoma: In this context, an oral combination therapy targeting dysregulation of NF-κB may be more effective in a population of DLBCL refractory to salvage immune-chemotherapy with R-DHAP, RICE, or similar cisplatin-Ifosfamide-etoposide-based regimens, particularly in view of the most recent data [44].